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Abstract: One promising field in neurovascular diseases investigation is the use of biomarkers to guide stroke etiology 
diagnosis and classification. Since treatment differs among etiologic subtypes and nowadays many patients receive a 
diagnosis of undetermined stroke, biomarkers might become an important additional diagnostic tool. In this review we 
update current knowledge about biomarkers related with cardioembolic stroke etiology (such as BNP and D-dimer 
proteins, or PITX2 and ZFHX3 genes), that in the future, might allow rapidly guiding other diagnostic tests and 
accelerating the onset of an optimal secondary prevention. 
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INTRODUCTION 
  The use of plasma biomarkers is getting increasingly 
popular in several fields of medicine. In fact, decision 
making processes using biomarkers are widely accepted in 
medical situations such as initiating lipid lowering therapies 
(by means of low-density lipoprotein plasma levels), 
diagnosing acute myocardial infarction (with troponins), 
ruling-out pulmonary embolism suspicions (by D-dimer 
levels), etc. Interest has also arrived to cerebrovascular 
diseases, since biomarkers might aid physicians in several 
steps of stroke evaluation [1]. 
  At present, the diagnosis of stroke remains based on 
clinical grounds and neuroimaging assessment. As neuro-
imaging is not a widely available tool, other methods might 
be useful to early differentiate between hemorrhagic and 
ischemic stroke or to discard pathologies that simulate 
cerebral ischemia, mainly in the pre-hospital setting. 
Biomarkers use might aid in ruling out these “mimics”, such 
as tumours or epileptic seizures, that account for up to a third 
of patients with stroke-like symptoms [2], thus avoiding 
unnecessary urgent transfers, specialist evaluation and extra-
testing and improving the cost-efectiveness in stroke field.  
  Nowadays intravenous thrombolysis with recombinant 
tissue-type plasminogen activator (rt-PA) remains the only 
approved acute treatment for ischemic stroke. However, 
despite great improvements in the field, still very few stroke 
patients (1-5%) benefit from these therapies [3]. That small 
number is due to the delay in hospital admission and diag-
nosis and the restrictive therapeutic window, since patients 
must be treated within 4.5 hours after stroke onset [4]. In this 
area, the applicability of biomarkers could help in improving 
safety and efficacy of the administration of reperfusion 
therapies. 
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  Once the diagnosis and hyperacute treatment of ischemic 
stroke have been done, etiologic classification is critical to 
discern the best treatment offered both in the stroke units 
during the acute phase and at the outpatient clinics for the 
secondary prevention. However, even with a thorough eval-
uation, the etiology of ischemic stroke remains undetermined 
in 25-39% of patients [5]. The use of biomarkers for etio-
logic diagnostic assessment, the focus of this review, might 
contribute to the reduction of this percentage of cryptogenic 
strokes and to prescribe the most appropriate secondary 
treatments (anticoagulant or antiplatelet therapy).  
STROKE ETIOLOGY CLASSIFICATION SYSTEMS  
  Given that stroke prognosis, risk of recurrence and 
choices for management greatly differ between stroke subty-
pes, several classifications schemes have been developed 
since the seventies in order to identify the most likely stroke 
etiology. 
  In 1993, a new classification system emerged: The 
TOAST classification [6], which is still the most popular 
method. According to this system, patients are classified in 
11 categories, which are further collapsed into 5 major 
etiologic groups including cardioembolic (CE) stroke. 
Interrater reliability was reported by these investigators to be 
only moderate (kappa=0.54) [7], and therefore, caution was 
recommended, since disagreements in subtype assignments 
would remain despite the use of these explicit criteria. 
Moreover, according to TOAST, stroke of undetermined 
etiology category would be applied to either patients having 
two or more definite etiologies or to patients having no cause 
after a negative extensive work-up, or to patients with 
incomplete evaluation, leading to great heterogeneity and 
usually oversizing the group of cryptogenic stroke.  
  These are the main reasons why new classifications have 
been appearing periodically, such as the Lausanne Stroke 
Registry and the GÉNIC classification [8, 9], which tried to 
decrease the number of patients classified as having an 
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cases from that group to the atherothrombotic stroke etiology 
category.  
  In 2005, Ay and colleagues [10] raised the question of 
whether diagnostic advances in stroke evaluation result in 
more frequent identification of vascular, cardiac and other 
systemic abnormalities and conflicting results could lead to 
categorization of most strokes into the undetermined causa-
tive category. To avoid the oversizing of the undetermined 
category, these authors developed an algorithm (SSS-
TOAST) that incorporated recent advances in stroke imaging 
and epidemiology to identify the most probable stroke 
etiology in the presence of evidence for multiple mecha-
nisms. Based on the weight of evidence, each TOAST sub-
type was subdivided into three subcategories: “evident”, 
“probable” or “possible”.  
  The SSS-TOAST assumes that imaging proof of acute 
infarction is required as a starting point to the accurate 
classification of ischemic stroke. As example, an otherwise 
evident or probable mechanism is lowered down to possible 
if there is no imaging proof of infarction in a location 
consistent with symptoms. Also, it is required that all 
patients are evaluated at a minimum level of diagnostic tests, 
which could be summarized on imaging of the brain 
(CT/MRI), imaging of extracranial and intracranial vessels 
(ultrasonography, CT angiography, MR angiography), moni-
toring the cardiac rhythm, function and structure (electro-
cardiogram, transthoracic echocardiography) and obtaining 
relevant blood tests. Further cardiac investigations may be 
considered relevant and then other cardiac tests (such as 
transesophageal echocardiography or Holter monitoring) are 
required. 
  The same authors [11] developed an automated version 
of the SSS-TOAST, the Causative Classification System 
(CCS), which is a web-based, questionnaire-style classifi-
cation scheme, to facilitate its use in multicenter studies [12] 
as shown in Fig. (1). Finally, it has to be considered that both 
TOAST classification and SSS-TOAST identify the most 
likely mechanism of stroke, without taking into account the 
interaction that might occur when two or more evident 
mechanisms co-exist. 
  In summary, although these classifications allow us to 
have a standard reference language, taken all together, they 
still have some important limitations. Moreover, these 
systems are based on associations, because they lack a gold 
standard, such as pathological confirmation, to define the 
exact cause of stroke. Thus, we should take them only as the 
basis of our diagnosis skeleton but we need to develop other 
ancillary tests to make a correct etiologic classification. Here 
is where the stroke biomarkers may have an important future 
role if an etiologic “biological signature” might be studied in 
accessible body fluids.  
BIOMARKERS TO IDENTIFY STROKE ETIOLO-
GIES 
  At present, only some approaches using biomarkers to 
evaluate the risk of ischemic stroke appearance are close to 
be applicable to clinic. That is the case of lipoprotein-
associated phospholipase A2 (Lp-PLA2), a circulating 
enzyme involved in inflammation that is an independent 
predictor of future stroke among healthy individuals [13]. In 
fact the FDA has approved recently the blood measurement 
of Lp-PLA2 to predict the risk of cardiovascular events. 
Therefore, early stroke detection will permit physicians to 
prescribe lifestyle changes in order to reduce some risk 
factors or establish preventive treatments. 
  Currently there is no single biomarker approved to iden-
tify stroke etiology. However several promising candidates 
have been recently described. In the next part of this review, 
we will summarize those studies that have tried to diffe-
rentiate stroke etiologies by using different blood bio-
markers.  
  The major difficulty in planning a study to identify a 
biomarker that would help to elucidate ischemic stroke 
etiology is the absence of a diagnostic standard for ‘stroke of 
undetermined etiology’, a situation where biomarkers are 
most needed. For this reason it would be very useful to have 
a complementary diagnostic tool that could define speci-
fically which etiology is involved in a stroke event in order 
to provide the optimal treatment.  
  The current research is mainly done in blood biomarkers 
since in a future clinic application the blood tests will be an 
accessible tool. In the next section, we will review the 
current knowledge about proteins, mRNA and polymor-
phisms studied as biomarkers of stroke etiology. Apart from 
these molecules, other types of biological elements could be 
indicative of processes related to the stroke pathology and 
they need to be taken into account, like protein fragments 
(such as D-dimer), peptides (such as telopeptide from 
collagen), aminoacids (such as asymmetric dimethylar-
ginine), lipids (such as ceramide) or blood particles (such as 
platelet-derived microparticles).  
  Moreover, we have included also some candidates that 
although have never been tested in stroke pathology are 
involved in some diseases considered as risk factors for 
stroke, or endophenotypes, like atrial fibrillation (AF) for CE 
stroke. All these promising biomarkers are listed on Table 1. 
PLASMA PROTEINS RELATED TO STROKE 
ETIOLOGY  
  These ideal candidates should be related to the main 
processes involved in stroke pathophysiology such as hemo-
stasis, inflammation, immune system activation, endothelial 
damage or oxidative stress. 
  Abnormalities of coagulation and fibrinolysis may play 
an important role in the pathogenesis of ischemic stroke. 
Thus, molecules involved in hemostasis might be useful 
biomarkers. For example, fibrinopeptide A and prothrombin 
fragment, that reflect thrombin activity, or D-dimer, a 
product of fibrin degradation, appear in the circulation when 
the coagulation system has been activated and red fibrin-rich 
thrombi have been formed. Those red clots typically 
originate in diseased cardiac chambers [14], being related to 
CE stroke etiology [15, 16] (Table 1).  
  In fact, Ageno and colleagues [17] described D-dimer as 
a marker of CE stroke in a cohort of 126 patients and 
according to day 1 measurements, the optimal cutoff point 
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specificity of 93.2% and in a sensitivity of 59.3%. In this 
direction and in the largest study ever conducted on 
biomarkers and stroke etiology, high levels of brain 
natriuretic peptide (BNP) and D-dimer were independent 
predictors of CE stroke in 707 ischemic stroke patients [16]. 
BNP >76 pg/mL OR=2.3 (95%CI, 1.4-3.7, P=0.001); and D-
dimer >0.96 microg/mL OR=2.2 (95%CI, 1.4-3.7, P=0.001) 
were independent predictors of CE stroke and even among 
patients with transient symptoms (n=155), a high BNP level 
identified CE etiology (OR= 6.7, 95%CI, 2.4-18.9; P<0.001). 
A model combining clinical and biochemical data had a 
sensitivity of 66.5% and a specificity of 91.3% for predicting 
cardioembolism. A practical example of the use of those 
types of models is shown in Fig. (1B). 
  This finding has been recently confirmed by Shibazaki 
and colleagues [18] who described an optimal cutoff 
concentration of plasma BNP level to distinguish CE from 
other stroke subtypes of 140.0 pg/mL, and extended to pro-
BNP by Rodríguez-Yáñez and collaborators [19], who 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A. Visual output from the Causative Classification System (CCS) in a hypothetical case of a 79 years old female patient, with a past 
history of hypertension, and an acute stroke (NIHSS=15) of undetermined cause using TOAST due to incomplete diagnostic work-up related 
to lack of all cardiac tests (sinusal rithm on EKG but Holter monitoring and transthoracic echocardiography not performed).  
B. Applying the predictive model described by Montaner and colleagues [16] we increase the risk of cardioembolic stroke from 8% to 36% 
in the presence of two high cardioembolic stroke related biomarkers (BNP and D-dimer). That would reinforce the necessity of performing 
all cardiac tests to evaluate a cardioembolic source and the necessity of anticoagulation.  Cardioembolic Stroke Biomarkers  Current Cardiology Reviews, 2010, Vol. 6, No. 3    197 
Table 1.  Candidate Markers of Cardioembolic Stroke, Based on Underlying Pathologies or Endophenotypes 
  Name  Accesion #  Reason for Being a Candidate  Ref. 
1  Adiponectin  Q15848  Elevated in patients with persistent AF.  [41] 
2  Angiopoietin-2 (Ang-2)  O15123  Angiogenic factor. Elevated in AF patients.  [29] 
3 Apelin  Q9ULZ1 
It seems to be involved in regulation of the angiotensin/vasopressin system. 
Lower levels in lone AF patients, correlating negatively with proBNP.  
[42] 
4  Asymmetric dimethylarginine (ADMA)   
Endogen inhibitor of NOS. ADMA contributes to the thromboembolism in 
AF. 
[43] 
5  Atrial natriuretic peptide (ANP)  P01160 
Marker of cardiac damage. Higher levels in CE stroke vs. other etiologies 
(262 patients). 
[19] 
6  Brain Natriuretic peptide (BNP)  P16860 
Higher plasma levels in patients suffering from acute CE strokes vs. other 
etiologies. Independent predictor of CE stroke.  
[16, 18, 
44, 45] 
7 
Brain natriuretic peptide, proform  
(pro-BNP) 
P16860 
Higher levels in CE stroke patients vs. other etiologies (262 patients). Pro-
BNP might be useful to reclassify undetermined stroke as of CE origin. 
[19] 
8 
Carboxy-terminal telopeptide of 
collagen type I (CITP) 
  Marker of collagen degradation. Elevated in patients with AF.  [41, 46] 
9  CD40 ligand, soluble (sCD40L)  P29965 
Inflammatory marker. Elevated in AF patients. No differencies found among 
etiologies within 107 acute ischemic stroke patients.  
[29, 31] 
10 CD63  P08962 
Platelet activation marker. More positive cells in AF patients (121 patients 
studied). 
[30] 
11 Coagulation  factor  VII  (FVII)  P08709 
A promoter polymorphism is associated with risk reduction of CE stroke in 
AF patients.  
[47] 
12  C-reactive protein (CRP)  P02741 
Risk marker for AF. Increased in acute CE stroke respect other etiologies 
(648 patients studied). 
[15, 24] 
13 D-dimer   
Breakdown product of fibrin, elevated in patients with AF. Independent 
predictor of CE stroke (707 ischemic stroke patients). 
[15-17] 
14  E-selectin, soluble   P16581  Marker of endothelial activation. Elevated in AF patients.  [48] 
15  Fibrinopeptide A  P02671  Increased in patients with AF. It reflects thrombin activity.  [15] 
16 Interleukin-1beta  (IL-1beta)  P01584 
Higher levels in subacute CE stroke vs. other etiologies (120 patients 
involved). 
[20] 
17 Interleukin-6  (IL-6)  P05231 
Pro-inflammatory cytokine. Elevated in AF patients and in subacute CE 
stroke vs. other etiologies (120 patients studied). 
[15, 20, 
25] 
18  Matrix metalloproteinase-1 (MMP-1)  P03956  Patients with AF had MMP-1 reduced.  [49] 
19  Matrix metalloproteinase-9 (MMP-9)  P14780  Elevated in AF patients vs. controls.   [50] 
20  Neuropeptide Y (NPY)  P01303  Elevated in AF patients vs. controls.   [50] 
21  Paired-like homeodomain (PITX2)  Q99697 
Transcription factor associated with AF. Gene polymorphism associated with 
CE stroke. 
[36, 37] 
22  Platelet factor 4 (PF-4)  P02776  Marker of platelet activation in AF patients.  [15] 
23  Platelet microparticles (PMP)    Higher number of particles in AF than in healthy controls.   [51] 
24  Prothrombin fragment 1.2 (F1+2)    Marker of thrombogenesis. Increased in AF patients.  [49] 
25  P-selectin (CD62P)  P16109  More positive cells in AF patients with high risk of stroke.   [30] 
26  p-Selectin, soluble  P16109  Marker of platelet activation in AF patients.  [15, 30] 
27  Tissue factor (TF)  P13726  Coagulation. Higher levels in AF patients.  [15] 
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  Name  Accesion #  Reason for Being a Candidate  Ref. 
28 
Tissue inhibitor of metalloproteinases-1 
(TIMP-1) 
P01033  Increased in AF patients.  [49] 
29 
Transforming growth factor-beta (TGF-
beta) 
P01137  Profibrotic cytokine. Higher levels predict persistent AF.  [52] 
30 
Tumor necrosis factor-alpha (TNF-
alpha) 
P01375 
Pro-inflammatory cytokine. Elevated in AF patients and in subacute CE 
stroke vs. other etiologies (120 patients studied). 
[15, 20] 
31 
Vascular endothelial growth factor 
(VEGF) 
P15692  Elevated in AF patients  [29] 
32  von Willebrand factor (vWF)  P04275 
Marker of endothelial damage/dysfunction. Higher plasma levels in AF 
patients, where predicts cardiovascular events. 
[15, 53] 
33  Zinc finger homeobox 3 (ZFHX3)  Q15911  Gene polymorphism associated with AF and CE stroke.   [38] 
 
studied 262 patients with first ischemic stroke within the first 
12 hours, showing that pro-BNP >360 pg/mL was indepen-
dently associated with CE stroke (OR=28.51, 95% CI, 5.90-
136.75, P< 0.0001). 
  Plasma levels of inflammatory and thrombotic markers in 
acute ischemic strokes were correlated with the TOAST 
subtype in a recent study by Licata and colleagues [20], 
showing how different the pro-inflammatory cytokines 
profile is between subtypes. In their study, Interleukin (IL)-
1beta, IL-6 and Tumor Necrosis Factor (TNF)-alpha were 
elevated in CE strokes as compared with other etiologies 
(Table  1). Otherwise, these cytokines had lower levels in 
stroke due to small vessel disease (SVD) when compared 
with all other stroke etiologies. The authors suggested that 
this might be explained by the different parenchymal zones 
affected by the infarct and consequently, by the different 
cellular components involved. Therefore, it seems that the 
immunological response has a different profile depending on 
stroke etiology. 
  This possible association between CE stroke and 
inflammation is suggested by several studies that are based 
on the identification of inflammatory serum biomarkers that 
are elevated in patients with AF. In this population, the 
successfulness of sinus rhythm maintenance after cardio-
version and the risk of CE stroke are related to the 
inflammatory burden. Indeed, inflammation and thrombosis 
are intimately related, and an association between AF and 
TNF-alpha has been demonstrated, moreover, patients with 
AF have higher levels of IL-6, plasma viscosity and tissue 
factor (TF), with the later relationship being maintained even 
after adjustment for confounding factors. 
  In this line of evidence, one of the most studied proteins 
is C-reactive protein (CRP), an acute-phase reactant protein 
that increases in response to different stimuli, like inflam-
mation or infection. It increases within 6 hours and has a 
peak at about 50 hours after stimulus [21]. CRP has rather 
been associated with large-artery atherosclerotic (LAA) 
events, on account of its involvement in the inflammatory 
process, platelet activation and macrophages differentiation 
to foam cells [22, 23]. However, Terruzzi and colleagues 
analyzed recently CRP plasma levels within the 6 first hours 
after stroke onset and showed higher levels in CE subset than 
in other etiologies [24]. These and other studies support the 
role of inflammation on heart diseases like AF [15, 25] 
(Table 1). Suggested explanations are that CRP is involved 
in the coagulation cascade, as CRP binds to phospholipids 
potencially activated by embolism, or that CRP levels are 
increased because the common largest extension of brain 
injury usually seen in CE strokes.  
  Nevertheless, some inflammatory markers have been 
certainly associated with LAA stroke, such as Lipoprotein A 
[Lp(a)]; that was evaluated in 253 consecutive patients with 
acute ischemic stroke in whom Lp(a) levels >30 mg/dL were 
more frequent among the LAA subgroup than among CE 
(39.4 vs. 11.1%; p < 0.001) [26].  
  Moreover, as there exist also white platelet-rich thrombi, 
platelet activation is another phenomenon that could provide 
with some good candidates, like CD40 ligand (CD40L), 
CD63 or P-selectin mainly associated with LAA strokes 
although these biomarkers have only been compared among 
non-CE strokes [27, 28]. However, some investigators have 
found elevated these markers in AF patients [29, 30], what 
reveal the necessity of studies that include all stroke 
etiologies. In fact, very recently, high levels of inflammatory 
markers shared by both LAA and CE strokes such as CD40 
ligand (CD40L) and fetuin-A have been described [31]. 
  A proteomic analysis in serum samples of 24 patients 
with ischemic stroke (12 LAA and 12 CE patients) identified 
four spots whose expression intensity was at least four times 
stronger in LAA patients than in CE patients: haptoglobin 
(Hp) related protein, serum amyloid A (SAA) (two spots) 
and Hp alpha chain. In a larger series of patients (n=262) 
with ischemic stroke using ELISA techniques, Hp levels 
>1,040 microg/mL identified LAA patients with 95% sensi-
tivity and 88% specificity whereas SAA levels > 160microg/ 
mL identified LAA patients with 91% sensitivity and 83% 
specificity [32].  
  The same group also studied 15-deoxy-Delta prostag-
landin J2 (15-d-PGJ2) in 552 patients with an acute stroke 
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of this prostaglandin were also significantly higher in 
patients with vascular risk factors (history of hypertension or 
diabetes) and with LAA infarcts (113.9 pg/mL [95% CI, 81.6 
to 139.7]), than in those with SVD (58.7 pg/mL [95%CI, 
32.7 to 86.2]), CE (12.1 pg/mL [95%CI, 6.5 to 39.2]), or 
undetermined origin infarcts (11.4 [5.6 to 24.3] pg/mL); 
P<0.0001. 
  The involvement of some pathways in several stroke 
etiologies reflects the complexity of finding good candidate 
biomarkers to identify CE strokes. Moreover, the charac-
teristics of the different studies performed (different cohorts, 
different end-points, different analytical conditions, patients’ 
treatments…) make hard to reach a consensus about the most 
suitable biomarkers involved in each etiology. In fact, some 
etiologies may share mechanisms (and therefore biomarkers) 
leading to stroke, such as a coronary disease that use to be 
atherothrombotic but may produce a cardiac discinesia or 
other heart disfunctions that generate an embolic stroke. The 
measurement of those markers at different time-points (acute 
versus subacute or chronic stages of neurovascular disease), 
includes also some other bias in these studies.  
  To overcome all those limitations, more studies involving 
a large number of ischemic stroke patients to compare 
biomarkers among etiologies should be done in the next 
future and it is likely that well-designed diagnostic trials will 
lead to clinical validation of selected stroke biomarkers.  
DIFFERENTIAL GENE EXPRESSION AMONG 
STROKE ETIOLOGIES 
  Although blood proteins have been the main molecules 
evaluated as biomarkers, recently some investigations 
support the usefulness of nucleic acids in the diagnosis of 
stroke. In 2008, Xu and colleagues presented the first study 
showing differences of gene expression when they compared 
CE versus LAA strokes [14]. Using RNA microarrays 
technology, they found 23 genes that can differentiate both 
etiologies with a high grade of specificity/sensitivity. Those 
patients suffering a LAA stroke showed an inflammatory 
profile, since they had upregulated genes expressed in plate-
lets (such as chemokines: PPBP, PF4, PDGFA and CCR5) 
and monocytes, both of them involved in the development of 
the atherosclerotic plaque. On the other hand, genes upre-
gulated in the CE etiology were expressed in neutrophils and 
modulate the immune response. 
  Another approach to use nucleic acids as biomarkers is 
by studying the microRNAs (miRNA), small non-coding 
RNAs, which control gene expression by both inhibition and 
activation. In a young Asian cohort, when comparing the 
expression profile of 836 miRNAs among CE, SVD and 
LAA strokes using microarrays, 132 miRNAs were useful in 
predicting etiology [34]. The miRNAs regulated were invol-
ved in endothelial/vascular function, angiogenesis, hemato-
poietic regulation and immune response.  
  Even though there are few reports in this field, the 
promising results obtained by means of these screening 
techniques using arrays should be analyzed with more detail 
in the future to find some combination of genes that could 
characterize each stroke etiology. Furthermore, these studies 
show how different the scenarios of the stroke   
pathophysiology are among etiologies and also which 
processes are altered depending on the cause of stroke.  
SPECIFIC GENE POLYMORPHISMS OF EACH 
STROKE ETIOLOGY  
  At present there are not many studies trying to identify 
genetic markers of etiology in ischemic stroke. Few analysis 
have attempted to find these biomarkers but with poor results 
[35] or with a limited sample size. The great majority of 
studies have focused in finding genetic risk factors for the 
different etiologies. In addition, the studies were focused in 
candidate gene approach, with no validation by other inde-
pendent studies.  
  The most promising results until now are referred to CE 
stroke and the use of Genome Wide Analysis (GWA) 
approaches. Several studies using GWAs, that detect over 1 
million of single-nucleotide polymorphisms (SNPs) across 
the genome, have observed significant signals in CE stroke. 
All these studies have identified SNPs that were associated 
also with AF, the main risk factor for CE stroke. The 
DeCODE group found a SNP in the Chromosome 4q25 
(rs2200733, near PITX2 gene) associated with ischemic 
stroke but only in CE etiology. This gene encodes a catenin-
regulated transcription factor associated with AF [36]. In this 
analysis, the DeCODE group genotyped 1,661 ischemic 
stroke cases and 10,815 controls using the Infinium 
HumanHap300 chip that detect over 300,000 SNPs. The 
most significant SNPs were replicated in two new different 
cohorts of 2,224 cases and 2,583 controls and in 2,327 cases 
and 16,760 controls. After the two replications were done, 
only rs2200733 was statistically associated with CE stroke 
[37]. Very recently a SNP in ZFHX3 gene has been asso-
ciated with AF and with CE stroke [38]. This gene encodes a 
homeodomain zinc-finger protein that has also been 
associated with AF. The rs7193343 variant of ZFHX3 gene 
was found after the analysis of 2,385 AF cases and 33,752 
controls. In a second phase the SNP was genotyped in five 
ischemic case-control sample sets of European descent com-
prising 1,036 cases and 3,468 controls and reaching signi-
ficant association.  
  Although there are not specific designed studies 
developed to find genetic differences between the etiologies 
of ischemic stroke, the second wave of GWAs in ischemic 
stroke that will be carried out next year might find these 
genetic differences through the promising use of endo-
phenotypes.  
DISCUSSION 
  Although there are many biomarkers that have been 
associated with stroke diagnosis, etiology or prognosis, 
information regarding clinical utility is extremely limited by 
the scarcity of large, prospective, rigorous, randomized 
clinical trials.  
  Massive sequencing of high quality, full-length cDNA 
libraries, coupled with proteomics and functional genomic 
approaches will bring a revolution in biomarkers discovery 
in the next years. Proteomics seems a promising tool for 
massive biomarkers identification in the stroke field, mainly 
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criptomics and GWAs studies are recently incorporating new 
candidate genes that might generate diagnostic and thera-
peutic targets for specific stroke etiologies. All generated 
candidates should be carefully validated before they are 
implemented in clinical routine.  
  The ideal biomarker should be very sensitive, specific, 
reliable, accessible, standardized, cost-effective and easy to 
interpret. Due to the complex pathophysiology of the stroke, 
a combined biomarker panel seems more feasible that a 
single biomarker for a diagnostic test [39]. Including bio-
markers from each stroke etiology or combining biochemical 
markers with bioimaging markers might be an alternative 
approach [40]. 
  Although point-of-care tools seem ideal in the stroke 
units setting, information would be useful even if obtained 
during the first days after stroke onset, allowing the use of 
standard platforms to get etiological biomarkers results. The 
use of such biomarkers would allow to drastically reducing 
the number of undetermined strokes. The identification of 
CE strokes in cases of paroxistic arrithmias is one of the 
main indications since this might produce an intensification 
of the secondary prevention and might be easily missed in 
routine examinations. For doing this therapeutical decisions 
we need a very specific test and for guiding other diagnostic 
tests a very sensitive biomarker would be needed.  
  Models of clinical data plus biomarker information and 
easy interpretation algorithms for clinicians would be 
mandatory if these markers have to be applied in daily 
practice. It is likely that future well-designed diagnostic trials 
will lead to clinical validation of selected stroke biomarkers. 
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ABBREVIATIONS 
15-d-PGJ2  =  15-deoxy-Delta protaglandin J2 
AF =  Atrial  fibrillation 
BNP  =  Brain natriuretic peptide 
CCR5  =  C-C motif chemokine 5 
CCS  =  Causative classification system 
CD40L =  CD40  ligand 
CE =  Cardioembolism 
CRP =  C-reactive  protein 
CT =  Computed  tomography 
FDA  =  Food and Drug Administration 
GÉNIC  =  Étude du profil génétique de l’Infarctus 
Cérébral 
GWA  =  Genome wide analysis 
Hp =  Haptoglobin 
IL-1beta =  Interleukin-1beta 
IL-6 =  Interleukin-6 
LAA =  Large-artery  atherosclerosis 
Lp(a) =  Lipoprotein  A 
Lp-PLA2 = Lipoprotein-associated  phospholipase  A2 
MRI  =  Magnetic resonance imaging 
PDGFA  =  Platelet-derived growth factor alpha 
PF4  =  Platelet factor 4 
PITX2 =  Paired-like  homeodomain 
PPBP  =  Pro-platelet basic protein 
rt-PA =  Recombinant  tissue-type  plasminogen 
activator 
SAA  =  Serum amyloid A protein 
SNP =  Single-nucleotide  polymorphism 
SVD  =  Small vessel disease 
TF =  Tissue  factor 
TNF-alpha  =  Tumor necrosis factor-alpha 
TOAST  =  Trial of Org 10172 in Acute Stroke 
Treatment 
ZFHX3  =  Zinc finger homeobox 3 
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